At ESMO TAT 2025, Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck, delivered a compelling presentation titled “Key Ingredients to Getting a Drug Combination Approved: Industry Perspective.”
In her talk, Dr. Green emphasized the importance of predictive preclinical models, biomarker-driven strategies, and thoughtful clinical trial designs to ensure both efficacy and safety. She also discussed how early engagement with regulatory authorities is critical to overcoming challenges and accelerating development timelines.
Her insights highlighted how combination strategies are becoming central in oncology innovation and underscored the industry’s responsibility to bring these therapies to patients efficiently and safely.
A valuable contribution from one of the field’s leading voices, reinforcing the collaborative effort needed across research, regulation, and industry to make meaningful progress.
